In antipsychotics’ square-off, were there winners or losers?

Investigators faced a dilemma while designing the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). More than 200 enrollees with chronic schizophrenia had pre-existing tardive dyskinesia (TD). Would it be ethical to give them the antipsychotic most likely to worsen their TD? Would exempting them from taking that drug influence the trial’s outcome?

This issue and others had to be resolved before the largest controlled study of “real world” schizophrenia could begin. Now that data are unfolding, groups with diverse agendas are debating CATIE’s methods and surprising results. This article describes how the trial’s design and findings could transform public policy and clinical practice.

**EFFICACY VS EFFECTIVENESS**

The National Institute of Mental Health funded the prospective CATIE schizophrenia study to compare the effectiveness of atypical antipsychotics versus each other and versus a first-generation (typical) antipsychotic.

All approved atypicals have shown similar efficacy compared with placebo in short-term trials...
The CATIE trial’s rationale is that short-term efficacy studies required for FDA approval may not necessarily reflect the drugs’ effectiveness in long-term schizophrenia management. Effectiveness measures take into account efficacy as well as safety, tolerability, and unpredictable patient behaviors in the real world.

**CATIE’S ‘REAL WORLD’ PATIENTS**

CATIE investigators enrolled a community sample of chronic schizophrenia patients similar to those many psychiatrists see. Very liberal inclusion and exclusion criteria (Table 1) allowed enrollees to have a history of substance abuse, comorbid psychiatric or medical disorders, be receiving other medications, or show evidence of TD. Their schizophrenia ranged from minimal to severe.

The 1,493 patients who completed the study (Table 2) were enrolled at 57 outpatient treatment settings. One site’s 33 patients were eliminated from analysis because of doubts about the integrity of the data, leaving a total of 1,460 subjects.

**Medications.** Before randomization, 28% of enrollees were not receiving antipsychotics. The remainder were receiving:

- olanzapine (22%)
- risperidone (19%)
- quetiapine (7%)
- ziprasidone (0%; approved after the trial began)
- any combination of olanzapine, risperidone, and quetiapine (7%)
- typical antipsychotics (16%).

**Metabolic profile.** These outpatients had a high rate of metabolic disorders: 42%—twice the rate in the general population—met criteria for metabolic syndrome, putting them at high risk to die of cardiovascular causes within 10 years.

---

**Table 1
Criteria for enrolling patients in the CATIE schizophrenia trial**

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ages 18 to 65 yrs</td>
<td>Diagnosis of schizoaffective disorder, mental retardation, or other cognitive disorders</td>
</tr>
<tr>
<td>DSM-IV diagnosis of schizophrenia</td>
<td>History of serious adverse reactions to one of the study medications</td>
</tr>
<tr>
<td>Able to take oral medication</td>
<td>Had only one schizophrenic episode</td>
</tr>
<tr>
<td>Able to give informed consent</td>
<td>History of treatment resistance, defined as persistence of severe symptoms despite adequate trials of one of the study antipsychotics or prior treatment with clozapine</td>
</tr>
</tbody>
</table>

Pregnant or breast feeding

Serious and unstable medical conditions

---

What do you think?
Go to the Instant Poll

www.currentpsychiatry.com

Will the CATIE findings change the way you treat patients with schizophrenia?

continued on page 53
They had relatively poor physical health self-ratings and increased somatic preoccupation. Most worrisome, many were receiving no medications for their metabolic disorders, including 45% of those with diabetes, 89% with hyperlipidemia, and 62% with hypertension.

**Substance abuse.** At enrollment, 40% of patients were abstinent from substance use, 22% were using substances without abuse or dependence, and 37% had substance abuse or dependence. Compared with nonusers, substance abusers tended to be male with more childhood problems, higher positive symptoms on the Positive and Negative Syndrome Scale (PANSS), and more likely to have had a recent illness exacerbation.

**Tardive dyskinesia.** The 231 subjects who met criteria for probable TD were older than the overall sample with more years of antipsychotic treatment, especially with conventional neuroleptics and anticholinergics. Substance abuse was associated with TD, as were severity of psychopathology, extrapyramidal symptoms (EPS), and akathisia.

**Violent behavior.** A history of serious violent behavior was reported in:

- 5.4% of patients with high positive and low negative PANSS symptom scores
- 1.7% of patients with low positive and high negative PANSS symptom scores.

**Consent.** Patients’ capacity to give consent to participate in the study was assessed with the MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR). Psychosis severity (PANSS positive symptom scale) was not found to affect decision-making capacity, but negative symptoms and diminished working memory did.

### CATIE’S UNIQUE DESIGN

**Defining effectiveness.** CATIE was designed in three phases (Figure, page 54). Phase 1—discussed here—was a blinded, controlled comparison of four atypical antipsychotics and per-

#### Table 2

<table>
<thead>
<tr>
<th>CATIE’s 1,460 ‘real world’ schizophrenia patients at trial entry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age: 40.6 ± 11.1 yrs</td>
</tr>
<tr>
<td>Mean age of first treatment: 24.0 ± 8.9 yrs</td>
</tr>
<tr>
<td>Mean duration of treatment: 14.4 ± 10.7 yrs</td>
</tr>
<tr>
<td>Gender: 74% male</td>
</tr>
<tr>
<td>Race: 60% white, 35% black, 5% other</td>
</tr>
<tr>
<td>Mean education: 12.1 ± 2.3 yrs</td>
</tr>
<tr>
<td>Marital status: 59% never married, 29% previously married, 11% married</td>
</tr>
<tr>
<td>Employment status: 85% unemployed</td>
</tr>
<tr>
<td>Mean PANSS total score: 75.7 ± 17.6</td>
</tr>
<tr>
<td>Mean CGI: 4.0 ± 0.9</td>
</tr>
<tr>
<td>Psychiatric comorbidities: 29% drug dependence/abuse, 28% depression, 25% alcohol dependence/abuse, 14% anxiety disorder, 5% obsessive-compulsive disorder</td>
</tr>
<tr>
<td>Illness severity: 4% severe, 20% marked, 47% moderate, 23% mild, 6% minimal</td>
</tr>
</tbody>
</table>

PANSS: Positive and Negative Syndrome Scale
CGI: Clinician-rated Clinical Global Impressions severity score
Source: Reference 5.
phenazin e. Results of phases 2 and 3 have yet to be published. The primary effectiveness endpoint, “all-cause discontinuation,” was defined as:
- lack of efficacy (patient was switched to another drug assigned at random)
- lack of tolerability (patient requested a drug change)
- safety problem (investigator initiated a switch)
- patient’s decision for any reason (often dropping out of the study).

The longer subjects stayed on the first antipsychotic they received, the more effective that drug was considered to be.

**Medications.** Three atypicals—risperidone, olanzapine, and quetiapine—were approved for schizophrenia when the trial began in 1999. Recruitment ended in June 2003, the last subject completed the 18-month trial in December 2004, and data analysis began in January 2005. Ziprasidone was added to phase 1 after 40% of the sample had been enrolled, and aripiprazole was included as an option in the unblinded phase 3.

Perphenazine was chosen to represent typical antipsychotics because it has medium potency and less risk of EPS than high-potency drugs such as haloperidol and is associated with less weight gain than low-potency drugs such as thioridazine.

**Dosing.** Pharmaceutical manufacturers donated the antipsychotics and were invited to recommend their respective drugs’ starting dosages, dose increments, and maximum dosages. Olanzapine’s maker requested a higher starting dosage (7.5 mg/d instead of 5.0 mg/d) and a maximum dosage 50% higher than the FDA-approved range (30 mg/d instead of 20 mg/d). The others recom-
recommended the FDA-approved dosage ranges or less:
- quetiapine, 200 to 800 mg/d
- risperidone, 1.5 to 6 mg/d
- ziprasidone, 40 to 160 mg/d
- perphenazine, 8 to 32 mg/d.

The study team accepted their recommendations.

The medications were packaged in identical capsules. Quetiapine and ziprasidone were given twice daily because of product labeling; risperidone, olanzapine, and perphenazine were given once daily to one-half the patients assigned to them and twice daily to the others to prevent raters from guessing which drug a patient was receiving.

Tardive dyskinesia. For ethical reasons, the 231 patients with TD at enrollment were randomly assigned in phase 1 to atypicals but not to perphenazine because of the well-established link between typical antipsychotics and TD. This exception could have contributed to the closer-than-expected differences in EPS and perhaps in efficacy, given reports that TD patients have more negative symptoms and cognitive dysfunction. However, a statistical analysis took that into account.

CATIE’S KEY FINDINGS

Discontinuation. A disappointingly high discontinuation rate (74% overall) within a few months was the most important finding (Table 3). A recent effectiveness study with a design similar to the CATIE trial found a similarly high rate of all-cause discontinuation (70%) in patients with first-episode psychosis. Thus, patient-initiated drug discontinuation appears to be a core illness behavior from schizophrenia onset to chronic illness.

The high discontinuation rate shows that we need to modify our approach to schizophrenia, emphasizing full adherence to antipsychotic therapy from the onset of the illness.

Effectiveness—measured as all-cause discontinuation or switching—was the primary outcome of phase 1. The unexpected finding that perphenazine and the atypicals had similar effectiveness could influence clinical practice. Insurers, for example, might consider promoting cheaper typical antipsychotics for first-line use. CATIE’s cost-effectiveness arm (Rosenheck et al, submitted for publication) will provide additional data on this issue.

---

Table 3

<table>
<thead>
<tr>
<th>Antipsychotic</th>
<th>Percent discontinued</th>
<th>Duration on antipsychotic (months)*</th>
<th>Dosage (mg/d)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olanzapine</td>
<td>64%</td>
<td>9.2</td>
<td>20.1</td>
</tr>
<tr>
<td>Perphenazine</td>
<td>75%</td>
<td>4.6</td>
<td>20.8</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>82%</td>
<td>4.8</td>
<td>543.4</td>
</tr>
<tr>
<td>Risperidone</td>
<td>74%</td>
<td>5.6</td>
<td>3.9</td>
</tr>
<tr>
<td>Ziprasidone</td>
<td>79%</td>
<td>3.5</td>
<td>112.8</td>
</tr>
<tr>
<td>Overall</td>
<td>74%</td>
<td>Median 6.0; mean 8.3</td>
<td></td>
</tr>
</tbody>
</table>

Notes
*Mean modal
Olanzapine’s discontinuation rate was significantly lower than those of perphenazine, quetiapine, and risperidone but not of ziprasidone.
Olanzapine’s maximum dosage was 20 mg/d (50% higher than FDA-approved 20 mg/d); other agents were dosed within approved ranges.
Patients reached maximum daily antipsychotic dosages at these rates: 40% with olanzapine, 40% with perphenazine, 44% with quetiapine, 40% with risperidone, and 48% with ziprasidone.
Before rushing to use older antipsychotics as first-line treatments for schizophrenia, however, policymakers should consider three factors in the study design that could have enhanced perphenazine’s efficacy and safety profiles.

First, perphenazine was given at lower dosages (up to 32 mg/d) than “real world” clinicians used a decade ago (up to 64 mg/d). Thus, lower rates of serious side effects, especially TD, might have occurred in the study than in past clinical practice. Since atypical antipsychotics were approved, clinicians see far fewer psychiatric patients with pill-rolling tremors, rigid posture, or a shuffling gait, compared with 10 to 15 years ago when typical antipsychotics were widely used.

Second, perphenazine was associated with the highest EPS rate (17%), though its mean modal dosage (20.8 mg/d) is considered moderate. Discontinuation because of EPS was highest with perphenazine and lowest with quetiapine.

**Table 4A**

<table>
<thead>
<tr>
<th>Rankings of effectiveness of antipsychotics in the CATIE trial, phase I</th>
</tr>
</thead>
<tbody>
<tr>
<td>Highest Effectiveness</td>
</tr>
<tr>
<td>Overall discontinuation rate*</td>
</tr>
<tr>
<td>Median duration on the antipsychotic (months)*</td>
</tr>
<tr>
<td>Discontinuation for efficacy reasons*</td>
</tr>
<tr>
<td>Discontinuation for tolerability reasons</td>
</tr>
<tr>
<td>Discontinuation due to weight gain*</td>
</tr>
<tr>
<td>Discontinuation due to EPS*</td>
</tr>
<tr>
<td>Discontinuation due to patient decision*</td>
</tr>
<tr>
<td>Duration of successful treatment (months)</td>
</tr>
<tr>
<td>Hospitalization*</td>
</tr>
</tbody>
</table>

* Statistically significant difference

O: olanzapine; R: risperidone; P: perphenazine; Z: ziprasidone; Q: quetiapine

EPS: extrapyramidal symptoms

Before rushing to use older antipsychotics as first-line treatments for schizophrenia, however, policymakers should consider three factors in the study design that could have enhanced perphenazine’s efficacy and safety profiles.

First, perphenazine was given at lower dosages (up to 32 mg/d) than “real world” clinicians used a decade ago (up to 64 mg/d). Thus, lower rates of serious side effects, especially TD, might have occurred in the study than in past clinical practice. Since atypical antipsychotics were approved, clinicians see far fewer psychiatric patients with pill-rolling tremors, rigid posture, or a shuffling gait, compared with 10 to 15 years ago when typical antipsychotics were widely used.

Second, perphenazine was associated with the highest EPS rate (17%), though its mean modal dosage (20.8 mg/d) is considered moderate. Discontinuation because of EPS was highest with perphenazine and lowest with quetiapine.

continued on page 81
### Table 4B

#### Safety, tolerability rankings among antipsychotics in the CATIE trial, phase 1

<table>
<thead>
<tr>
<th>Side effect rates</th>
<th>Highest</th>
<th>O 16%</th>
<th>Q 18%</th>
<th>R 18%</th>
<th>P 25%</th>
<th>Z 30%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insomnia*</td>
<td></td>
<td>Z 20%</td>
<td>P 22%</td>
<td>O 24%</td>
<td>R 25%</td>
<td>Q 31%</td>
</tr>
<tr>
<td>Urinary hesitancy, dry mouth, constipation*</td>
<td>Q 13%</td>
<td>O 14%</td>
<td>= Z 14%</td>
<td>R 16%</td>
<td>&lt; P 17%</td>
<td></td>
</tr>
<tr>
<td>EPS and TD</td>
<td></td>
<td>Q -3.0</td>
<td>O -2.0</td>
<td>R -1.6</td>
<td>= O -1.0</td>
<td>= P -0.4</td>
</tr>
<tr>
<td>Use of anticholinergic medication</td>
<td>Q 3%</td>
<td>O 8%</td>
<td>= Z 8%</td>
<td>R 9%</td>
<td>&lt; P 10%</td>
<td></td>
</tr>
<tr>
<td>Weight gain (mean in lbs), phase 1*</td>
<td>P -2.0</td>
<td>Z -1.6</td>
<td>&lt; R 0.8</td>
<td>= Q 1.1</td>
<td>&lt; O 9.4</td>
<td></td>
</tr>
<tr>
<td>Proportion of subjects with &gt;7% body weight gain*</td>
<td>Z 7%</td>
<td>&lt; P 12%</td>
<td>&lt; R 14%</td>
<td>&lt; Q 16%</td>
<td>&lt; O 30%</td>
<td></td>
</tr>
<tr>
<td>Weight gain per month of treatment (mean in lbs)*</td>
<td>Z -0.3</td>
<td>&lt; P -0.2</td>
<td>&lt; R 0.4</td>
<td>&lt; Q 0.5</td>
<td>&lt; O 2.0</td>
<td></td>
</tr>
<tr>
<td>Blood glucose rise (mean mg/dL)</td>
<td>Z 2.3</td>
<td>&lt; P 5.2</td>
<td>&lt; R 6.7</td>
<td>&lt; Q 6.8</td>
<td>&lt; O 15.0</td>
<td></td>
</tr>
<tr>
<td>Hg A1C % change*1 (exposure adjusted mean)</td>
<td>Q 0.04</td>
<td>&lt; R 0.07</td>
<td>&lt; P 0.09</td>
<td>&lt; Z 0.11</td>
<td>&lt; O 0.40</td>
<td></td>
</tr>
<tr>
<td>Cholesterol change*1</td>
<td>Z -8.2</td>
<td>&lt; R -1.3</td>
<td>&lt; P 1.5</td>
<td>&lt; Q 6.6</td>
<td>&lt; O 9.4</td>
<td></td>
</tr>
<tr>
<td>Triglycerides change*1</td>
<td>Z -16.5</td>
<td>&lt; R -2.4</td>
<td>&lt; P 9.2</td>
<td>&lt; Q 21.2</td>
<td>&lt; O 40.5</td>
<td></td>
</tr>
<tr>
<td>Prolactin changes*1</td>
<td>Q -10.6</td>
<td>&lt; O -8.1</td>
<td>&lt; Z -5.6</td>
<td>&lt; P -1.2</td>
<td>&lt; R 13.8</td>
<td></td>
</tr>
<tr>
<td>Corrected QTC (mean msec from baseline)</td>
<td>R 0.2</td>
<td>&lt; O 1.2</td>
<td>&lt; Z 1.3</td>
<td>&lt; P 1.4</td>
<td>&lt; Q 5.9</td>
<td></td>
</tr>
<tr>
<td>New cataracts (# of cases per sample)</td>
<td>Z 0/142</td>
<td>&lt; O 1/258</td>
<td>&lt; P 1/210</td>
<td>&lt; R 2/260</td>
<td>&lt; O 3/272</td>
<td></td>
</tr>
<tr>
<td>Anxiolytic added*</td>
<td>O 9%</td>
<td>&lt; R 10%</td>
<td>&lt; Q 14%</td>
<td>&lt; Z 15%</td>
<td>= P 15%</td>
<td></td>
</tr>
</tbody>
</table>

O: olanzapine; R: risperidone; P: perphenazine; Z: ziprasidone; Q: quetiapine

* Statistical significant difference

*1 Exposure adjusted mean mg/dL

---

Continued from page 56
Third, excluding enrollees with TD from perphenazine may have increased perphenazine’s effectiveness, whereas including them in the atypicals groups may have reduced the atypicals’ effectiveness. TD patients are at increased risk to develop EPS; they had more-severe illness and a higher substance abuse rate among CATIE patients.\(^{11}\) Even so, investigators did control for TD in the data analysis and found no significant difference between typical and atypical antipsychotics.

**NO 'WINNERS' OR 'LOSERS'**

Effectiveness, tolerability, and safety findings for each antipsychotic are compared in Tables 4A and 4B. Careful review shows no clear “winners” or “losers;” each agent has weaknesses but also strengths that may benefit individual patients.

**Efficacy.** Olanzapine showed a relatively higher efficacy and lower discontinuation rate but also had the highest risk of adverse metabolic effects. Some have attributed its greater efficacy to its higher dosing compared with the other antipsychotics. Some also have argued that the antipsychotics that showed lower efficacy, such as quetiapine and ziprasidone, were underdosed in this chronic schizophrenia population with a mean duration of illness of 14 years. Perphenazine, too, was dosed at the lower end of its range (mean modal dose 20.8 mg/d) compared with the old community standard of 36 to 64 mg/d.

Generally, a mean modal dosage of 20.1 mg/d for olanzapine is considered equivalent to ziprasidone, 160 mg; quetiapine, 800 mg; and risperidone, 6 mg. In CATIE phase 1, mean modal dosages were:

- ziprasidone, 112.8 mg/d (30% below 160 mg)
- quetiapine, 543.4 mg/d (32% below 800)
- risperidone, 3.9 mg/d (35% below 6 mg).

Olanzapine’s starting dosage of 7.5 mg/d was relatively higher than those of the other atypicals, which may have produced more-rapid onset of efficacy.

**Switching.** Another potential “advantage” for olanzapine was that 22% of subjects were taking it when they enrolled. By random assignment, 23% of patients who were taking olanzapine stayed on olanzapine and did not switch. By comparison:

- No patients assigned to ziprasidone were taking it before entering the trial.
- Only 5% of those taking quetiapine stayed on that drug after randomization.
- Few were receiving perphenazine before enrollment.

Switching antipsychotics may increase side effect risk or efficacy problems. For example, a patient switched from olanzapine or quetiapine to ziprasidone or perphenazine may experience insomnia during the transition, which may lead to tolerability complaints.

**Metabolic side effects** seen in this trial support past observations and reports that olanzapine is associated with higher risk for weight gain, hyperglycemia, and hyperlipidemia than other antipsychotics.\(^ {15}\) Data on metabolic changes in CATIE patients taking olanzapine are being analyzed.

---

**Bottom Line**

Phase 1 of the CATIE schizophrenia trial found four atypical and one typical antipsychotic similarly effective for ‘real world’ patients. Drug dosage decisions and selective randomization of patients with tardive dyskinesia may explain these results. Discontinuation rates averaged 74%, and side effects varied.

---

\(^ {11}\) Data on metabolic changes in CATIE patients taking olanzapine are being analyzed.

---

Continued on page 65
Hyperprolactinemia was most common with risperidone and practically nonexistent with other antipsychotics—even perphenazine. On the other hand, risperidone had the most favorable tolerability profile. This implies that elevated prolactin does not necessarily lead to antipsychotic discontinuation because of tolerability among patients with schizophrenia.

QTC interval and cataract data were benign across all antipsychotics. These findings appear to exonerate ziprasidone and quetiapine, respectively, which have been perceived as associated with these side effects.

COMING NEXT
When data become available, the next article in this series will discuss CATIE phase 2 findings. This phase includes patients who did not improve with the phase 1 regimens because of efficacy or tolerability problems and were switched to other antipsychotic therapies.

References

Related resources
- Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study. www.catie.unc.edu/schizophrenia

DRUG BRAND NAMES
- Aripiprazole • Abilify
- Olanzapine • Zyprexa
- Perphenazine • Tralafon
- Quetiapine • Seroquel
- Risperidone • Risperdal
- Ziprasidone • Geodon

DISCLOSURE
Dr Nasrallah receives grants/research support from AstraZeneca, Janssen Pharmaceuticals, Eli Lilly & Company, and Pfizer Inc. He is a consultant, advisory board member, and speaker for Abbott Laboratories, AstraZeneca, Janssen Pharmaceuticals, Pfizer Inc., and Shire Pharmaceuticals Group.